JP2021506790A - 塩形態の有効成分を含むマイクロニードルアレイ - Google Patents
塩形態の有効成分を含むマイクロニードルアレイ Download PDFInfo
- Publication number
- JP2021506790A JP2021506790A JP2020532587A JP2020532587A JP2021506790A JP 2021506790 A JP2021506790 A JP 2021506790A JP 2020532587 A JP2020532587 A JP 2020532587A JP 2020532587 A JP2020532587 A JP 2020532587A JP 2021506790 A JP2021506790 A JP 2021506790A
- Authority
- JP
- Japan
- Prior art keywords
- microneedle array
- salt form
- active ingredient
- intradermal delivery
- microneedles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical group 0.000 title claims abstract description 41
- 239000004480 active ingredient Substances 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 9
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 9
- 238000009472 formulation Methods 0.000 claims abstract description 9
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims description 15
- 229960004207 fentanyl citrate Drugs 0.000 claims description 13
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 11
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 229960001889 buprenorphine hydrochloride Drugs 0.000 claims description 2
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920001971 elastomer Polymers 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 229920000111 poly(butyric acid) Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000005060 rubber Substances 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000035515 penetration Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 24
- 239000010408 film Substances 0.000 description 17
- 210000000434 stratum corneum Anatomy 0.000 description 15
- 239000004821 Contact adhesive Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- -1 polyethylene Polymers 0.000 description 9
- 229960001736 buprenorphine Drugs 0.000 description 7
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012790 adhesive layer Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 229920006262 high density polyethylene film Polymers 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 239000002313 adhesive film Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011104 metalized film Substances 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
さらなる実施形態によれば、マイクロニードルアレイは、ニードルパッチとも呼ばれるコンタクト接着剤の細片またはパッチによって患者または被験者の皮膚に好ましくは貼着される固定手段を備え得る。適切なコンタクト接着剤は、感圧接着剤(PSA)として知られる弱い圧力を軽く加えた後に皮膚に貼着する高粘度物質を含む。これらは高い凝集力および接着力を有する。例えば、ポリ(メタ)アクリレート系、ポリイソブチレン系またはシリコーン系のコンタクト接着剤を使用することが可能である。さらなる実施形態では、固定手段はバンド、弾性バンド、ゴムまたはストラップで作製されていてもよい。そのような固定手段によって、身体への確実な固定を実現することができる。
Claims (9)
- 担体上に複数のマイクロニードルを備えた、塩形態の有効成分の皮内送達で使用するためのマイクロニードルアレイであって、該マイクロニードルは、少なくとも1種の塩形態の有効成分および少なくとも1種の生分解性ポリマーを含有する製剤を含むことを特徴とする、前記マイクロニードルアレイ。
- 塩形態の有効成分は、塩形態の医薬であることを特徴とする、請求項1に記載の塩形態の有効成分の皮内送達で使用するためのマイクロニードルアレイ。
- 塩形態の有効成分は、塩形態の鎮痛薬、特にクエン酸フェンタニルまたは塩酸ブプレノルフィンであることを特徴とする、請求項1または2に記載の塩形態の有効成分の皮内送達で使用するためのマイクロニードルアレイ。
- 生分解性ポリマーは、水溶性ポリマーであることを特徴とする、請求項1〜3のいずれか1項に記載の皮内送達で使用するためのマイクロニードルアレイ。
- 生分解性ポリマーは、ポリビニルピロリドン、ポリビニルアルコール、セルロース、デキストラン、乳酸および/またはグリコール酸のようなアルファヒドロキシ酸、ポリラクチド、ポリグリコリド、ポリラクチド−co−グリコリド、ならびにそれらとポリエチレングリコールとのコポリマー、ポリ酸無水物、ポリ(オルト)エステル、ポリウレタン、ポリ酪酸、ポリ吉草酸およびポリラクチド−co−カプロラクトンからなる群から選択されることを特徴とする、請求項1〜4のいずれか1項に記載の皮内送達で使用するためのマイクロニードルアレイ。
- マイクロニードルアレイは、平面であることを特徴とする、請求項1〜5のいずれか1項に記載の皮内送達で使用するためのマイクロニードルアレイ。
- 担体上のマイクロニードルの密度は、5個/cm2〜5000個/cm2であることを特徴とする、請求項1〜6のいずれか1項に記載の皮内送達で使用するためのマイクロニードルアレイ。
- マイクロニードルアレイは、特に接着性の細片、パッチ、バンド、弾性バンド、ゴムまたはストラップからなる群から選択される固定手段を備えることを特徴とする、請求項1〜7のいずれか1項に記載の使用のためのマイクロニードルアレイ。
- 請求項1〜8のいずれか1項に記載の皮内送達で使用するためのマイクロニードルアレイを備えるアプリケーターシステムであって、該アプリケーターシステムは、トリガ機構を備えることを特徴とする、前記アプリケーターシステム。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024000392A JP2024039052A (ja) | 2017-12-14 | 2024-01-05 | 塩形態の有効成分を含むマイクロニードルアレイ |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102017130057 | 2017-12-14 | ||
DE102017130057.0 | 2017-12-14 | ||
PCT/EP2018/085083 WO2019115815A1 (de) | 2017-12-14 | 2018-12-14 | Mikronadelarray aufweisend einen wirkstoff in form von salzen |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024000392A Division JP2024039052A (ja) | 2017-12-14 | 2024-01-05 | 塩形態の有効成分を含むマイクロニードルアレイ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021506790A true JP2021506790A (ja) | 2021-02-22 |
JP2021506790A5 JP2021506790A5 (ja) | 2022-01-06 |
Family
ID=65011948
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020532587A Pending JP2021506790A (ja) | 2017-12-14 | 2018-12-14 | 塩形態の有効成分を含むマイクロニードルアレイ |
JP2024000392A Pending JP2024039052A (ja) | 2017-12-14 | 2024-01-05 | 塩形態の有効成分を含むマイクロニードルアレイ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024000392A Pending JP2024039052A (ja) | 2017-12-14 | 2024-01-05 | 塩形態の有効成分を含むマイクロニードルアレイ |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200297985A1 (ja) |
EP (1) | EP3723725B1 (ja) |
JP (2) | JP2021506790A (ja) |
CN (1) | CN111542309A (ja) |
BR (1) | BR112020010729A2 (ja) |
CA (1) | CA3085633A1 (ja) |
ES (1) | ES2908820T3 (ja) |
WO (1) | WO2019115815A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017112573A1 (de) * | 2017-06-07 | 2018-12-13 | Lts Lohmann Therapie-Systeme Ag | Mikronadelsystem zur Applikation von Glukagon-ähnlichen-Peptid Analoga |
DE102019129444A1 (de) | 2019-10-31 | 2021-05-06 | Lts Lohmann Therapie-Systeme Ag | Lagtime-Verkürzung/Eisspray |
CN113520986A (zh) * | 2021-06-16 | 2021-10-22 | 暨南大学 | 一种任意曲面聚合物微针阵列及其制备方法 |
DE102021118997A1 (de) | 2021-07-22 | 2023-01-26 | Lts Lohmann Therapie-Systeme Ag. | Mikronadelarray mit Antiseptika |
DE102021130950A1 (de) * | 2021-11-25 | 2023-05-25 | Lts Lohmann Therapie-Systeme Ag. | Applikationshilfe |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007532645A (ja) * | 2004-04-13 | 2007-11-15 | アルザ コーポレイション | フェンタニルに基づく薬剤の経皮送達システム用の器具および方法 |
JP2010516337A (ja) * | 2007-01-22 | 2010-05-20 | コリウム インターナショナル, インコーポレイテッド | マイクロニードルアレイ用アプリケータ |
CN102406640A (zh) * | 2010-09-26 | 2012-04-11 | 上海泰因生物技术有限公司 | 镇痛消炎类药物及镇痛消炎类药物微针透皮给药方法 |
JP2013536875A (ja) * | 2010-09-07 | 2013-09-26 | オレクソ・アクチエボラゲット | 経皮薬物投与デバイス |
WO2016142705A1 (en) * | 2015-03-09 | 2016-09-15 | Emplicure Ab | A transdermal drug administration device |
WO2016162449A1 (de) * | 2015-04-07 | 2016-10-13 | Lts Lohmann Therapie-Systeme Ag | Mikronadelsystem zur applikation von flüssigen formulierungen |
JP2017051312A (ja) * | 2015-09-08 | 2017-03-16 | 富士フイルム株式会社 | マイクロニードルアレイ |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6780171B2 (en) * | 2002-04-02 | 2004-08-24 | Becton, Dickinson And Company | Intradermal delivery device |
DE10353629A1 (de) | 2003-11-17 | 2005-06-16 | Lts Lohmann Therapie-Systeme Ag | Vorrichtung zur transdermalen Verabreichung von Wirkstoffen |
US20080008745A1 (en) * | 2006-06-21 | 2008-01-10 | University Of Kentucky Research Foundation | Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles |
US20090182306A1 (en) * | 2006-07-21 | 2009-07-16 | Georgia Tech Research Corporation | Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal |
DE102007041557B4 (de) * | 2007-08-29 | 2011-03-31 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System enthaltend längliche Hohlkörper |
MX2010010512A (es) * | 2008-03-26 | 2010-11-09 | Alltranz Inc | Formulaciones transdermicas de agonistas y antagonistas-agonistas de opiato que impiden el abuso. |
JP2009254756A (ja) * | 2008-04-14 | 2009-11-05 | Kosumedei Seiyaku Kk | マイクロニードルアレイ |
CN101612141B (zh) * | 2009-07-29 | 2012-10-03 | 考司美德制药株式会社 | 丁丙诺啡贴剂 |
US9017289B2 (en) * | 2010-11-03 | 2015-04-28 | Covidien Lp | Transdermal fluid delivery device |
AU2012225609B2 (en) * | 2011-03-07 | 2015-10-01 | Kindeva Drug Delivery L.P. | Microneedle devices and methods |
JP2013032324A (ja) * | 2011-08-03 | 2013-02-14 | Bioserentack Co Ltd | 局所麻酔薬を含有する即効性のマイクロニードル・アレイ・パッチ製剤 |
EP2919849B1 (en) * | 2012-11-16 | 2021-01-06 | Kindeva Drug Delivery L.P. | Force-controlled applicator for applying a microneedle device to skin |
EP3932463A1 (en) * | 2013-01-08 | 2022-01-05 | Kindeva Drug Delivery L.P. | Applicator for applying a microneedle device to skin |
JP2016517707A (ja) * | 2013-03-22 | 2016-06-20 | スリーエム イノベイティブ プロパティズ カンパニー | カウンタ組立体を備えているマイクロニードルアプリケータ |
MX353241B (es) * | 2013-05-31 | 2018-01-05 | 3M Innovative Properties Co | Aparato de inyección de microagujas que comprende un accionador invertido. |
EP3003269A1 (en) * | 2013-05-31 | 2016-04-13 | University Of The Witwatersrand, Johannesburg | Polymeric hydrogel pharmaceutical compositions with on-demand release of a drug ain response to a electrical stimulus |
CN103550191A (zh) * | 2013-10-15 | 2014-02-05 | 温天文 | 一种布洛芬及其盐无痛微针透皮贴剂及其制备方法 |
-
2018
- 2018-12-14 CA CA3085633A patent/CA3085633A1/en active Pending
- 2018-12-14 ES ES18833180T patent/ES2908820T3/es active Active
- 2018-12-14 US US16/771,586 patent/US20200297985A1/en active Pending
- 2018-12-14 JP JP2020532587A patent/JP2021506790A/ja active Pending
- 2018-12-14 CN CN201880080460.6A patent/CN111542309A/zh active Pending
- 2018-12-14 WO PCT/EP2018/085083 patent/WO2019115815A1/de active Search and Examination
- 2018-12-14 BR BR112020010729-8A patent/BR112020010729A2/pt active Search and Examination
- 2018-12-14 EP EP18833180.5A patent/EP3723725B1/de active Active
-
2024
- 2024-01-05 JP JP2024000392A patent/JP2024039052A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007532645A (ja) * | 2004-04-13 | 2007-11-15 | アルザ コーポレイション | フェンタニルに基づく薬剤の経皮送達システム用の器具および方法 |
JP2010516337A (ja) * | 2007-01-22 | 2010-05-20 | コリウム インターナショナル, インコーポレイテッド | マイクロニードルアレイ用アプリケータ |
JP2013536875A (ja) * | 2010-09-07 | 2013-09-26 | オレクソ・アクチエボラゲット | 経皮薬物投与デバイス |
CN102406640A (zh) * | 2010-09-26 | 2012-04-11 | 上海泰因生物技术有限公司 | 镇痛消炎类药物及镇痛消炎类药物微针透皮给药方法 |
WO2016142705A1 (en) * | 2015-03-09 | 2016-09-15 | Emplicure Ab | A transdermal drug administration device |
WO2016162449A1 (de) * | 2015-04-07 | 2016-10-13 | Lts Lohmann Therapie-Systeme Ag | Mikronadelsystem zur applikation von flüssigen formulierungen |
JP2017051312A (ja) * | 2015-09-08 | 2017-03-16 | 富士フイルム株式会社 | マイクロニードルアレイ |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol. 35, JPN6022051706, 2016, pages 1 - 7, ISSN: 0005144225 * |
Also Published As
Publication number | Publication date |
---|---|
US20200297985A1 (en) | 2020-09-24 |
ES2908820T3 (es) | 2022-05-04 |
EP3723725B1 (de) | 2022-02-02 |
WO2019115815A1 (de) | 2019-06-20 |
JP2024039052A (ja) | 2024-03-21 |
BR112020010729A2 (pt) | 2020-11-10 |
CN111542309A (zh) | 2020-08-14 |
CA3085633A1 (en) | 2019-06-20 |
EP3723725A1 (de) | 2020-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021506790A (ja) | 塩形態の有効成分を含むマイクロニードルアレイ | |
JP5267910B2 (ja) | マイクロニードルアレイ | |
KR101724655B1 (ko) | 마이크로 니들 패치 및 그의 제조 방법 | |
US20090035357A1 (en) | Method of drug delivery using a transdermal device having a phase change material | |
JP4763612B2 (ja) | 活性物質を経皮投与するためのデバイス | |
US20180326195A1 (en) | Microneedle array and microneedle sheet | |
US8439861B2 (en) | Skin penetrating touch fasteners | |
KR200479627Y1 (ko) | 마이크로 니들 패치 | |
JPWO2019176146A1 (ja) | マイクロニードルパッチ及びマイクロニードルパッチの製造方法 | |
JP2023130489A (ja) | 創傷治癒のための活性成分を含むマイクロニードルアレイを備えるアプリケータシステム | |
CN106853271B (zh) | 微结构体的制造方法 | |
HU206992B (en) | Method for producing transdermal system advantageously plaster suitable for controlled feeding active ingredient | |
JP2015116335A (ja) | 経皮薬剤投与システム及び経皮薬剤投与システムの製造方法 | |
KR101724654B1 (ko) | 마이크로 니들 패치 및 그의 제조 방법 | |
KR20170132087A (ko) | 사마귀 치료를 위한 블레오마이신을 함유하는 마이크로니들 패치 및 이의 제작방법 | |
RU2652567C1 (ru) | Микроигольный аппликатор и способ его изготовления | |
US20220143375A1 (en) | Microneedle array comprising a heat-producing element | |
Sowmya et al. | Transdermal therapeutic systems—An overview | |
CA3223732A1 (en) | Microneedle array with antiseptics | |
Roy | Use and Improvement of Microneedles in Diabetes Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20200715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211124 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230609 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240105 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240228 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240426 |